Centhaquine

Centhaquine (brand name Lyfaquin) is a cardiovascular drug.[1] In India, it is approved for the treatment of hypovolemic shock.[2]

Centhaquine
Clinical data
Trade namesLyfaquin
Other namesCenthaquin; PMZ-2010; Compound-7173
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2-[2-[4-(3-Methylphenyl)piperazin-1-yl]ethyl]quinoline
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25N3
Molar mass331.463 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3
  • InChI=InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3
  • Key:UJNWGFBJUHIJKK-UHFFFAOYSA-N

Centhaquine is a vasopressor acting on α2A- and α2B-adrenoreceptors.[3] It increases venous return and improves tissue perfusion.

References
  1. Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997. PMID 33970455.
  2. "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.
  3. Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi:10.3390/ijms25063494. PMC 10970680. PMID 38542464.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.